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ABSTRACT
The human immunodeficiency virus (HIV) epidemic is clearly one of the most serious health-care
crises in the professional lives ofcontemporary physicians. It cannot be regarded as a curiosity to be
dealt with by inner-city infectious-disease experts, but rather must be considered a problem for all
health-care providers and a problem in which the obstetrician-gynecologist has a special role to
play. (C) 1994 Wiley-Liss, Inc.
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as the human immunodeficiency virus (HIV)
epidemic really abated? There is evidence of a
leveling off of new cases in the gay male population
generally, although a recent resurgence has been
reported among young gay males in San Francisco.
There is no indication of a decrease in new cases in
drug abusers, their sexual partners, or their chil-
dren. In many of America’s inner cities, acquired
immunodeficiency syndrome (AIDS) is the leading
cause of death among women in the reproductive-
age group and a more frequent cause of perinatal
death than any of the so-called "TORCH" infec-
tions. AIDS in drug users is a disease of families,
leaving growing numbers of youth orphaned. An
estimation has been made that, unless the course of
the epidemic changes, 80,000 children and adoles-
cents will be orphaned by the year 2000.1 Even in
areas of lower prevalence, it behooves the obstetri-
cian to consider the diagnosis and offer testing along
with appropriate counseling to his or her patients.
EPIDEMIOLOGY
As of September 30, 1993, 339,250 cases that meet
the Centers for Disease Control (CDC) definition
of AIDS have been reported in the United States.
Newly expanded definitions will increase the accu-
mulation rate. New York City, NY, has reported
56,581 cases, accounting for 17% of the national
total. Of these, 18% are women and 2% are chil-
dren.
2 As many as 200,000 individuals (3.5%) of
the population of that city are estimated to be HIV
positive. This means that, for every symptomatic
individual, 20-30 individuals have no symptoms
at alJ and are, for the most part, unaware of their
infection. Fewer than 5% of those infected can be
expected to develop AIDS within 5 years, and the
mean interval is more than 10 years. Available
prospective data suggest that, barring dramatic ther-
apeutic developments, 99% of infected individuals
will probably go on to develop symptoms.
3 Al-
though there are no good data concerning women,
the median survival in men following the diagnosis
is 24 months with a 5-year survival of 3.4%. This
rate will undoubtedly increase as more effective
therapy is applied. The burden on our health-care
system is enormous. On any given day in New
York City, more than 3,000 acute-care beds are
occupied by patients with HIV infection.
Drug use now accounts for the majority of new
cases ofHIV infection and nearly all perinatal HIV
infections. Of the estimated 200,000 intravenous
(IV)-drug users in New York, of whom 75% are
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males, most are sexually active and 50-70% are
HIV positive. Drug-use patterns change, and there
has been a recent resurgence of heroin use along
with increased polydrug abuse. Crack cocaine has
also contributed to the problem as its use has in-
creased. Because it is rapidly addicting and short
acting, needs are great and often met by women
users through the exchange of sex-for-drugs. This
situation has led to a concomitant dramatic increase
in sexually transmitted diseases along with a failure
to obtain adequate or often any prenatal care. The
Kings County Hospital in Brooklyn sees significant
numbers of patients who have received no prenatal
care. In a survey of unregistered patients, 48%
were found to have positive urine screens for co-
caine metabolites; 17% had positive serologies for
syphilis, a rate 1,400 times the national average;
and 7% were HIV positive.
Because of" the association between poverty and
drug abuse in inner-city populations as Well as of
secondary heterosexual spread, HIV infection dis-
proportionately affects ethnic minorities. In New
York, 63% of males with HIV are black or Latino,
while the figure for women is 85% and for children
90%.
2
Both the absolute numbers and the percentage of
women with HIV infection are increasing. Among
women with symptomatic AIDS, 61% of the cu-
mulative cases are the result of their own drug use,
while 23% of cases are assigned to drug-using sex-
ual partners.
2 AIDS is the leading cause of death in
women between ages 15 and 44 years in New York
and the fifth leading cause of death of all American
women in the reproductive-age group. Women,
more often than men, have no identifiable risk
behavior which poses a significant problem when
selective screening is employed. The seropreva-
lence in obstetric populations varies widely from
0.15% in the United States to a high of 12% in
Zambia in Central Africa. A statewide anonymous
cord-blood survey in New York showed a preva-
lence of 1/61 (1.6%).
4
IMPACT OF PREGNANCY ON THE
COURSE OF HIV INFECTION
The concern is whether or not the altered immune
status of pregnancy might increase the morbidity or
mortality from HIV infection as it is thought to do
with other viral diseases such as influenza, hepati-
tis, and varicella, in which the host response is
largely cell mediated, Early reports included case
studies of mortalities in symptomatic pregnant
women. In fact, the first 5 patients reported with
AIDS in pregnancy all died of opportunistic infec-
tions.
6-8 Such mortality data must be viewed cau-
tiously, however, since they may reflect reporting
bias, or delay, in diagnosis and treatment during
pregnancy, perhaps because of fetal concerns. An-
other perspective can be obtained from the fol-
low-up of asymptomatic women whose seropositiv-
ity is detected by their having delivered children
who developed AIDS. These women have gener-
ally done poorly, with the majority progressing to
symptomatic disease in a relatively short period of
follow-up.
9 An alternative explanation is that these
women were simply prone to both perinatal trans-
mission and disease progression. Prospective stud-
ies comparing HIV-positive pregnant and nonpreg-
nant women are ongoing, and the available reports
demonstrate little or no difference in the rate of
clinical or immunologic deterioration. 1’1 It is
likely that a more important determinant is the
stage of the HIV infection at the time of the preg-
nancy. In a study in which I-IIV-positive gravidas
were monitored with CD4 counts, those with counts
<300 proved more likely to develop opportunistic
infections during pregnancy,
12 raising the question
of the use of prophylactic azidothymidine (AZT) or
pentamidine under such circumstances.
IMPACT OF HIV INFECTION ON
PREGNANCY OUTCOME
Most studies fail to demonstrate an impact of as-
ymptomatic HIV infection on the common param-
eters of pregnancy outcome such as birth weight,
preterm delivery, and premature rupture of the
membranes.
13-s Reports that seem to show an ef-
fect on outcome include more women with symp-
toms, indicating a more advanced stage of I-IIV
infection. 9’6 These studies are also complicated by
confounding variables such as poor nutrition and
substance abuse, making them even more difficult
to interpret.
The earliest reports of the rate of perinatal trans-
mission varied widely, and prospective studies were
impeded by the lack of a practical antigen test and
the fact that passively acquired antibody in the new-
born may take as long as 15 months to clear. Other
methods, such as polymerase chain reaction, viral
culture, and IgA antibody determination, are being
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17 explored to facilitate earlier neonatal diagnosis.
The best estimate of the rate of vertical transmis-
sion is 20-30% with one notable exception. The
European collaborative study reported a rate of
13%.
18 With a view toward developing a means of
fetal protection, we have focused considerable at-
tention on the factors that might influence the rate
of perinatal transmission. An advanced stage of
disease and CD4 counts of <400/ram
3 are associ-
ated with an increased rate of transmission. While a
few studies have suggested that maternal antibodies
to certain epitopes of the GP120 envelope glyco-
protein seem to reduce the rate,
19 other studies
20 have not been able to replicate the latter findings.
Considerable attention is now focused on the timing
and mechanisms of maternal-fetal transmission,
but these factors are not yet thoroughly clarified.
HIV can be transmitted as either free virus or cell-
associated virus, in this case, in mononuclear cells.
Studies have demonstrated that maternal mononu-
clear cells can enter the fetal circulation and can be
identified in 10-20% of pregnant women. HIV
can also be recovered from cord blood in 20-30%
of infected women and has been isolated from
aborted central nervous system (CNS) tissue at 20
weeks gestation.
21 Both free and cell-associated vi-
ruses have been isolated by cervical and vaginal
lavage, making intrapartum transmission a possi-
bility.
22 Although prior studies have indicated that
a cesarean section does not prevent perinatal infec-
tion,
18 more recent evidence indicates that it may
be at least partially protective. Trials are also un-
derway to determine whether AZT administration
antepartum, intrapartum, or during the neonatal
period can reduce transmission.
As concerns the neonatal outcome, 93% of the
pediatric cases in New York are the result of per-
inatal transmission and 78% of those cases relate to
drug use.
2 Of the remaining cases, blood transfu-
sion accounts for most, but there is insufficient
information to assign a category in 3% of the cases.
Significantly, in only 11% of the perinatally trans-
mitted cases did the parents have diagnosed AIDS
at the time the diagnosis was established in the
child. The prognosis in these children is often poor
despite aggressive treatment. There do, however,
appear to be 2 groups of children with HIV infec-
tion with different clinical courses. One group in-
cludes those who develop symptoms in the first 6
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months of life and rarely survive beyond year of
age. Increasingly, we are recognizing a second
group that includes those who remain mildly in-
fected for several years. Characteristically, those in
the latter group have interstitial pneumonitis while
those with the acute short course are more likely to
have pneumocystis pneumonia or encephalitis.
23
ROLE OF THE OBSTETRICIAN
Education and Testing
The first challenge and the primary role for the
obstetrician lie in counseling and testing since, in
most circumstances, once an infected patient is iden-
tified, she will be referred to or at least comanaged
with an expert in HIV. From the onset of the
epidemic, questions have been raised in determin-
ing who should be tested over the conflicting prin-
ciples of public health vs. the protection of an indi-
vidual’s civil rights. Some have pressed for
mandatory testing, citing historic examples such as
syphilis. That approach poses several problems.
One concern is that there have been, and continue
to be, violations of the civil liberties of families and
individuals which are not prevented by our current
laws.
24-26 Another concern is that mandatory test-
ing may cause women who might be at risk to avoid
care for fear of being identified. Perhaps the great-
est concern, at least at the outset of the epidemic,
and the major flaw in the syphilis analogy, is that
there is so little to offer from a therapeutic or
preventive standpoint.
2s This argument has be-
come less compelling as more effective therapy has
become available. Mandatory testing also fails to
provide the protection providers seek for them-
selves, since the screening detects antibodies that,
in the extreme case, may not appear for 18 months
after infection. The availability ofa reliable antigen
test could obviate this problem.
Another option posed was premarital testing,
but it too has serious problems. The results in
Illinois were disastrous with exorbitant costs per
case identified and a marked drop in marriage li-
censes issued, indicating that couples likely obtained
their licenses in neighboring states. Currently, the
most common approach is testing based upon the
identification of patients with risk factors such as
immigration from an endemic area like Central
Africa, a bisexual partner, or a history of transfu-
sion prior to the institution of screening the blood
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supply. The difficulty with selective testing, espe-
cially in high-prevalence areas, is that a significant
number of seropositive individuals will have no
history of risk factors.
27 In one study, more than
40% of prenatal patients who subsequently proved
to be seropositive gave no history of risk factors
when questioned by specially trained interviewers.
Health departments often report lower figures for
the absence of risk factors, but this information is
generally obtained at interviews with the test results
in hand.
Because of these data and because the seropreva-
lence in the obstetric population at our institution
exceeds 2% and that of the State of New York is
|.6%,
4 we have elected to counsel and offer testing
to all pregnant women. If risk factors are present,
the counseling is more positive. This policy of "in-
formed refusal" permits women to reject testing
after being appropriately counseled. This approach
has now been adopted by the New York State De-
partment of Health. The downside is the burden of
providing proper counseling to a large population
of patients, since it is both time and personnel
intensive and cannot be done effectively in groups.
It also requires educating the counselors, be they
obstetricians, midwives, nurses, or other health-
care professionals, in order to ensure the quality of
the information in providing a proper basis for
patients’ decisions. The most recent guidelines from
the CDC urge us to recommend, offer, or make
available testing, depending upon the local preva-
lence. It should be noted that the false-positive rate
is very high with enzyme-linked immunosorbent
assay (ELISA) screening alone, especially in low-
prevalence populations.
28 These results must be
confirmed by a more specific test such as the West-
ern blot.
When this "informed refusal" approach was ini-
tiated, 40-50% of our patients accepted testing and
3% were positive, a prevalence slightly higher than
the overall rate, perhaps indicating a degree of
self-selection. When the counseling language was
changed from "offering" to "recommending" test-
ing, the acceptance rate rose to 70%. It is also
important to note that, in follow-up counseling, a
significant number ofwomen will continue to deny
risk behavior and only a small number, approxi-
mately 10%, will opt for pregnancy termination
when identified sufficiently early to permit it.
29
There is still no universally accepted approach to
testing; however, as more effective therapy becomes
available, it will be increasingly acceptable to rec-
ommend testing to all pregnant women, as
Testing of physicians and other health-care per-
sonnel is also a controversial issue. While there was
considerable notoriety concerning a Florida dentist
who allegedly infected several of his patients, the
facts in that case remain less than clear. Although
physician-to-patient transmission is theoretically
possible, its frequency is exquisitely low and thor-
oughly documented cases are rarely found in the
literature. Fortunately, an effort by the CDC to
develop a list of "risk-prone procedures" that could
not be performed by HIV-positive physicians was
thwarted for lack of any scientific basis. The cur-
rent policy specifies that the clinical activities of an
HIV-positive physician should be determined and
monitored locally by a committee of doctors expert
in the area, including the physician’s own care pro-
viders.
Counseling
Although some patients are aware of their HIV
status at the time they seek prenatal care, a more
common scenario is that their seropositivity is dis-
covered as a result of the initial counseling and
testing at the first prenatal visit. The next step is
post-test counseling. This step is also important for
the woman who has a negative serology, especially
if she continues her risk behavior despite the physi-
cian’s advice.
26 Periodic testing should be done at
an interval sufficient to allow for seroconversion.
The standard recommendation is 6 months although
the conversion interval may vary from the usual
6-12 weeks to as long as 18 months.
For the I--IIV-positive woman, counseling should
address the following issues:26’3
1. A description of the early manifestations of
AIDS and the need to seek attention when they
occur.
2. An accurate understanding o the prognosis,
which s obviously difficult considering its na-
ture.
3. The need to practice safe sex and avoid needle
sharing.
4. A prohibition from donating blood or organs.
5. Advice against sharing implements that might
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY 79HIV INFECTION AND PREGNANCY SCHWARZ
TABLE I. Protocol for HIV-positive
pregnant patients
38
Prenatal
CD4 count each trimester (more frequently if low)
Tests at first visit
Toxoplasmosis antibody
Cytomegalovirus antibody
Mantoux tuberculin test
Hepatitis surface antigen
B-2 macroglobulin
VDRL
Gonococcal culture
Chlamydia culture
Cryptococcal antigen
SMA-12
Pneumovax influenza vaccine and hepatitis B vaccine
administered as indicated
Tests at delivery
Urinalysis for cytomegalovirus
Repeat toxoplasmosis antibody and cytomegalovirus antibody
if negative at first visit
be contaminated with blood, such as razors or
toothbrushes.
6. Advice that the test results should be shared
with sex and needle-sharing partners and that
they should seek counseling and testing as well.
7. Advice that health-care workers dealing with
the patient should be informed by the patient of
her HIV positivity. Unfortunately, this infor-
mation often makes it difficult for the patient to
obtain care. The medical record is the ideal
place to communicate with other health profes-
sionals, but access to these records is often not
limited to those with legitimate need.
Antenatal Management
Counseling and psychosocial support form the cor-
nerstone ofantenatal management. These steps must
be taken, if possible, sufficiently early in preg-
nancy to empower all of the patient’s reproductive
options. Whether or not the patient chooses to con-
tinue the pregnancy, the stresses are enormous and
support systems must be developed and maintained
throughout and beyond the pregnancy.
Screening for other infections, such as toxoplas-
mosis and cytomegalovirus, is critical since sexual
as well as perinatal transmission are common to a
number of these diseases. The procedures to be
carried out prenatally are listed in Table 1. The
patient should receive pneumococcal influenza vac-
cine (Pneumovax, Merck, Sharp & Dohme, West
Point, PA) and, if indicated by a negative surface-
antigen test, hepatitis B vaccine. The regular mea-
surements of CD4 counts can identify patients at
risk for disease progression and opportunistic in-
fection. If the count falls below 500, the use of
zidovudine (Retrovir AZT, Burroughs Wellcome
Co., Research Triangle Park, NC) should be dis-
cussed with the patient. While almost all would
recommend AZT if the count falls to 200, the
200-500 range remains a debatable are.
31,32 AZT
has not been conclusively evaluated in pregnancy;
however, animal studies have not demonstrated ei-
ther mutagenicity or teratogenicity. AZT acts by
inhibiting reverse transcriptase, and this mecha-
nism of itself poses no specific threat. AZT does,
however, cross the primate placenta and, conse-
quently, has the potential to cause anemia in the
fetus as it does in the adult.
33 In addition to moni-
toring the maternal hemoglobin, it is well to moni-
tor the fetus with ultrasound for growth retardation
or the possibility of fetal hydrops which could re-
sult from severe fetal anemia. Recent reports sug-
gest that the anemia in adults can be reversed by the
use of erythropoietin. More information is being
gathered on AZT in pregnancy, but, for now, we
must maintain a balance in our thinking in order
not to place the mother at risk because of fetal
concerns. It is not prudent to recommend routine
AZT for all HIV-positive pregnant women, but it
should be considered for those with low CD4
counts. Although we have no data concerning
women, clearly, a count <200 indicates a signifi-
cant risk for pneumocystis.
34 For this reason, a
woman with a count <200 should be offered aero-
sol pentamidine prophylaxis. There are no conclu-
sive studies on the safety of pentamidine during
pregnancy; however, when it is administered by
aerosol, serum concentrations reach only 5% of the
dose given. Trimethoprim/sulfamethoxazole, now
the first line, is an effective alternative approach.
Its side effects include fever, rash, and neutrope-
nia.
35
It may be more difficult to evaluate the HIV-
infected patient during pregnancy because some
symptoms such as fatigue and weight loss might be
dismissed as pregnancy related when, in fact, they
indicate a progression of HIV disease. Patients
should be advised to report all symptoms. They
also should be provided with nutritional counseling
and encouraged to maintain normal weight gain.
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Should an opportunistic infection develop, con-
sultation with an infectious-disease specialist is es-
sential since these infections are complex to manage
and life threatening. Generally, there is little rea-
son to withhold any antibiotic in the face of such a
grave prognosis. The most common opportunistic
infection, particularly in pregnancy, is Pneumocys-
tis carinii pneumonia and the accepted treatment is
trimethoprim/sulfamethoxazole along with penta-
midine. Concerns about sulfa competing for bili-
rubin-binding sites in the fetus are overstated, es-
pecially under these circumstances. Other
opportunistic infections that occur much less fre-
quently in pregnancy include CNS toxoplasmosis;
oral, vaginal, and esophageal candidiasis; crypto-
coccus meningitis; cytomegalovirus; and herpes.
Recently, drug-resistant tuberculosis has emerged
as an increasingly frequent and difficult problem.
Labor Management
Although no controlled studies back this recom-
mendation, the use of scalp sampling and scalp
electrodes is not advisable since the best protection
for the fetus is intact skin. The current recom-
mendation as to the mode of delivery is that a
cesarean section be reserved for obstetric indica-
tions only and that this procedure does not prevent
perinatal transmission. In an earlier German study
in which elective cesarean delivery was carried out
in consecutive HIV-positive women, 9/20 infants
were infected despite abdominal delivery. More
recently, studies of twins suggested the highest risk
for a first-born twin delivered vaginally; a lower
risk for a first-born twin delivered by cesarean
section; and the lowest risk for a second-born
twin.
a6 The implications are that further quantita-
tively important studies could well lead to revised
policies regarding the mode of delivery. The new-
born should be carefully cleansed of maternal blood
and secretions, with particular attention to prepara-
tion of the infant’s skin before drawing blood.
Postpartum Management
There is little information about the postpartum
course in HIV-infected women, but no evidence
that it is significantly altered. The virus has, how-
ever, been isolated from breast milk and case re-
ports indicate that mothers have acquired HIV in-
fection from postpartum transfusions and then
transmitted it to their infants by breast-feeding. In
another report in which known seropositive women
breast-fed their infants, the rate of vertical trans-
mission was no greater than that ofwomen who did
not breast-feed.
37 Breast-feeding should be avoided
if there is a suitable alternative, as there is in the
developed world. Obviously, in some parts of the
world, this alternative does not exist. A final step in
the care of the infected pregnant woman is to make
certain that she receives continuing care from a
knowledgeable and sensitive physician, which is
not always a simple matter because not a large num-
ber of physicians are willing to provide such care.
CONCLUSIONS
The HIV epidemic is clearly one of the most, if not
the most, serious health-care crises in the profes-
sional lives of contemporary physicians. It cannot
be regarded as a curiosity to be dealt with by inner-
city infectious-disease experts, but rather must be
considered a problem for all health-care providers
and a problem in which the obstetrician-gynecolo-
gist has a special role to play.
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